While JAK2 inhibition ameliorates MPN phenotypes driven by JAK2 or related gene mutations in both mouse models and humans, its impact on excessive myelopoiesis and atherogenesis caused by hypercholesterolemia and defective cholesterol efflux from HSPCs and myeloid progenitors is unknown. This evidence concerns the gene JAK2 and familial hypercholesterolemia.